Treatment and management of myelofibrosis in the era of JAK inhibitors

@article{Keohane2013TreatmentAM,
  title={Treatment and management of myelofibrosis in the era of JAK inhibitors},
  author={C. Keohane and D. Radia and C. Harrison},
  journal={Biologics : Targets \& Therapy},
  year={2013},
  volume={7},
  pages={189 - 198}
}
Myelofibrosis (MF) can present as a primary disorder or evolve from polycythemia vera (PV) or essential thrombocythemia (ET) to post-PV MF or post-ET MF, respectively. MF is characterized by bone marrow fibrosis, splenomegaly, leukoerythroblastosis, extramedullary hematopoiesis, and a collection of debilitating symptoms. Until recently, the therapeutic options for patients with MF consisted of allogeneic hematopoietic stem cell transplant (alloHSCT), the use of cytoreductive agents (ie… Expand
Treatment of Myelofibrosis: Old and New Strategies
The future of JAK inhibition in myelofibrosis and beyond.
Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics
Update in the myeloproliferative neoplasms.
Myelofibrosis patients in Belgium: disease characteristics

References

SHOWING 1-10 OF 75 REFERENCES
Therapeutic approaches in myelofibrosis
How I treat symptomatic splenomegaly in patients with myelofibrosis.
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.
...
1
2
3
4
5
...